We have in-house capabilities to develop complex generics in a wide range of dosage forms, including complex parentals, complex ophthalmic solutions, suspensions and gels. On July 29, 2022, we had filed one INDA for an anti-diabetic NCE molecule, which is in phase I clinical trials. As of December 31, 2022, we had two NCE molecules for autoimmune diseases and non-alcoholic steatohepatitis in pre-clinical stage. We are developing novel drug delivery systems for inhalation solutions and pulmonary drug delivery, including dry-powder inhalers, metered-dose inhalers and oral films. In addition, we are strengthening our capabilities in product portfolios such as NCEs and Paragraph IV products. Further, our biotechnology team is in the process of developing several biosimilars (including monoclonal antibodies) for anti-allergic and anti-cancer treatments.